CARLSBAD, Calif., Aug. 5, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67 percent in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA). Patients treated with ISIS-CRPRx showed improvements in signs and symptoms of RA; however, these improvements were not statistically significant when compared to those observed in patients in the placebo group, which demonstrated a higher than expected response in both symptom score and CRP reduction. A Phase 2 study of ISIS-CRPRx in patients with atrial fibrillation is currently ongoing with data anticipated in the first half of 2014.
And based on the entire ISIS story with their pipeline, and all the partnerships and early approval of the flagship drug, today's news is insignificant, so I'm not sure why there are a few people trying to sell in pre-market. 200 shares, down $1.23?